EQS-News: Formycon AG / Key word (s): Regulatory Approval Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE® ...
Regulatory ApprovalFormycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE® 25.02.2025 / 06:30 CET/CESTThe issuer is solely ...
Sanofi and Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd., today presented new, detailed results from the RELIEVE UCCD phase 2b study of duvakitug, a human IgG1-λ2 ...
Detailed price information for Teva Pharmaceutical Industries ADR (TEVA-N) from The Globe and Mail including charting and trades.
In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDIâ„¢for all indicationsmatching the reference product ...
As Hamas handed over the bodies of four murdered hostages, Israelis gathered in grief, marking a painful moment in the ...
Axsome will grant Teva a license to sell its generic version of Auvelity beginning on or after March 31, 2039, if pediatric ...
As consumers and brands alike search for sustainable alternatives, one company is leading the charge in transforming the ...
Sound Shore Management, an investment management firm, has released its investor letter for the fourth quarter of 2024. A ...
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA led the market today, rising 2.22% on the day's biggest trading turnover. ICL (TASE: ICL: NYSE: ICL) rose 5.43% and parent company Israel ...
U.S. President Donald Trump's administration needs to speed up generic drug approvals and exempt some drugs from funding ...
U.S. President Donald Trump's administration needs to speed up generic drug approvals and exempt some drugs from funding ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback